Ocugen Replaces Top Medical Officer as Cash Runway Extends to 2028 — But Stock Stays Stuck in Oversold Territory

Ocugen stock drops 26% in 30 days as CMO resigns, but OCU400 BLA on track for 2026; $113M cash runway and Stifel forum offer catalysts.

Ocugen enters a critical stretch with two open fronts: a sudden change in its medical leadership and an investor event on the horizon. The stock, meanwhile, continues to trade deep in oversold territory, closing at €1.18 on Friday after a 5.29% daily drop. Over the past 30 days, the shares have shed 26.22% — a slide that has pushed the relative strength index to 25.3 and widened the gap to the 50-day moving average to roughly a quarter. With annualized 30-day volatility at 90.79%, the swings have become violent.

Yet the underlying pipeline story has not soured. Ocugen’s most advanced asset, OCU400, remains on track for a rolling BLA submission starting in the third quarter of 2026, with completion targeted for the second quarter of 2027. Process validation batches are slated for the second quarter of 2026. The liMeliGhT phase 3 study in retinitis pigmentosa has finished recruitment and covers a wide range of genetic mutations — a foundation for the regulatory path ahead. For OCU410ST, aimed at Stargardt disease, an interim analysis of 24 patients at eight months post-treatment is planned for the third quarter of 2026, with topline data expected in the second quarter of 2027.

That clinical momentum now has to absorb a leadership shakeup. Huma Qamar stepped down as chief medical officer effective May 8, and Ocugen appointed Mohamed Genead as interim medical chief on the same day. The company provided few details on the departure, which naturally draws scrutiny given the tight interplay between clinical strategy, regulatory preparation, and medical communication at this stage of development.

On the financing side, Ocugen recently closed a $130 million convertible note, netting roughly $113 million after costs. The company immediately used a portion to retire an existing loan. At closing, cash, cash equivalents, and restricted cash are expected to total $112.1 million, enough to fund operations into 2028. If the remaining Janus Henderson warrants are exercised, an additional $15 million in gross proceeds could follow. That liquidity cushion buys time for three planned regulatory submissions — including the OCU400 BLA — but it also comes at a cost: the quarterly loss per share widened slightly to $0.06, and operating expenses rose.

The next visible catalyst is the Stifel Virtual Ophthalmology Forum at the end of May. Ocugen’s management will present to investors and a scientific audience, with the recording available for 30 days afterward. The appearance follows a recent presentation at the Retina World Congress and offers a chance to reinforce confidence in the pipeline. Analysts at Oppenheimer and Chardan Capital have maintained buy ratings despite the stock’s slide.

The immediate task for Ocugen is clear: stabilize the transition in medical leadership, use the Stifel forum to underscore clinical progress, and keep the manufacturing preparation for OCU400 moving ahead without friction. Until the BLA submission begins in the third quarter of 2026, the market will be watching for any cracks in the timeline — or fresh reasons to believe the oversold signal can finally translate into a recovery.